FLT1 and preeclampsia: Importantly, the ratio of soluble fms-like tyrosine kinase 1 (sFlt) to placental growth factor (PlGF) was recently approved by the FDA for clinical utilization as a predictor of preeclampsia risk over either biomarker individually [26].